Table 1.
Baseline Characteristics in START, Overall and According to Primary Event Status (n = 4299)
| Median [IQR], n (%) | P Valueb | |||
|---|---|---|---|---|
| Overall | Primary Eventa | No Primary Eventa | ||
| Participants | 4299 | 129 | 4170 | |
| Demographics | ||||
| Age, y | 36 [29–44] | 44 [34–51] | 36 [29–44] | <0.001 |
| Female gender | 1141 (26.5) | 27 (20.9) | 1114 (26.7) | 0.14 |
| Race | 0.042 | |||
| Black | 1301 (30.3) | 41 (31.8) | 1260 (30.2) | |
| White | 1938 (45.1) | 68 (52.7) | 1870 (44.8) | |
| Other | 1060 (24.7) | 20 (15.5) | 1040 (24.9) | |
| Medical history | ||||
| Duration of HIV diagnosis, y | 1.0 [0.4–3.0] | 1.2 [0.5–3.6] | 1.0 [0.4–3.0] | 0.34 |
| CD4,c cells/µL | 651 [584–765] | 632 [584–742] | 651 [584–765] | 0.26 |
| CD8+, cells/µL | 1040 [775–1399] | 1081 [799–1505] | 1040 [774–1395] | 0.12 |
| CD4:CD8 ratio | 0.66 [0.48–0.89] | 0.61 [0.42–0.82] | 0.66 [0.48–0.89] | 0.031 |
| HIV RNA, copies/mL | 12 911 [3120–43 730] | 22 726 [7485–63 956] | 12 647 [3057–42 889] | 0.001 |
| Hepatitis B/C | 276 (6.5) | 10 (7.8) | 266 (6.5) | 0.54 |
| Prior CVDd | 25 (0.6) | 3 (2.3) | 22 (0.5) | 0.04 |
| BMI, kg/m2 | 24.5 [22.1–27.8] | 24.6 [22.5–27.7] | 24.5 [22.1–27.8] | 0.66 |
| Current smoking | 1398 (32.5) | 57 (44.2) | 1341 (32.2) | 0.004 |
| Biomarkers | ||||
| D-Dimer, μg/mL | 0.33 [0.23–0.50] | 0.40 [0.29–0.66] | 0.32 [0.22–0.49] | <0.001 |
| IL-6, pg/mL | 1.39 [0.97–2.12] | 1.65 [1.26–2.57] | 1.38 [0.96–2.11] | <0.001 |
| hsCRP, μg/mL | 1.71 [0.74–4.01] | 1.89 [0.93–4.54] | 1.69 [0.73–3.97] | 0.07 |
| SAA, mg/L | 4.52 [2.53–8.75] | 5.68 [3.15–9.77] | 4.47 [2.51–8.74] | 0.014 |
| IL-27, pg/mL | 251 [126–520] | 261 [118–506] | 251 [126–521] | 0.97 |
| sICAM, μg/mL | 541 [423–693] | 622 [502–751] | 538 [422–691] | <0.001 |
| sVCAM, μg/mL | 722 [62–922] | 808 [28–987] | 720 [61–919] | 0.004 |
Abbreviations: BMI = body mass index; CVD = cardiovascular disease; hsCRP = high-sensitivity C-reactive protein; IL = interleukin; IQR: interquartile range; MI = myocardial infarction; SAA = Serum Amyloid A; sICAM = soluble intercellular adhesion molecule; SNA = serious non-AIDS events, sVCAM = soluble vascular cellular adhesion.
Primary event refers to the composite study end point of AIDS, SNA, or death.
P value comparing those with a primary event with those without a primary event. Medians were compared using Wilcoxon rank-sum tests and proportions compared using chi-square tests. The Fisher exact test was used for comparison of prior CVD risk.
Average of screening and baseline values.
MI, coronary revascularization, or stroke.